Articles about Psychedelic

• President Trump has moved to fast-track psychedelic research as part of his administration's policy agenda, marking a significant shift in federal drug policy priorities. • Former Arizona Senator Kyrsten Sinema has publicly applauded the initiative as a "bold step forward" in medical research on Fox & Friends Weekend. • The accelerated psychedelic research program represents an innovative approach to mental health treatment and scientific advancement under the Trump administration.

• The FDA announced it will issue national priority vouchers for three psychedelic drugs next week, marking the first time the agency has fast-tracked any psychedelics for review under Trump's executive order on mental health reform. • The vouchers can compress FDA review timelines from several months to just weeks, according to FDA Commissioner Marty Makary, if the drugs align with national priorities. • Trump's order directs $50 million in federal funding to states developing psychedelic treatment programs and establishes a federal-state partnership for technical assistance and data sharing.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaineDonald Trump on Saturday announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs.The president signed an executive order directing the federal Food and Drug Administration (FDA) to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder. Continue reading...

Analysis of more than 500 brain scans finds LSD, psilocybin and other psychedelics increase cross-talk between brain systemsScientists have identified a hallmark signature produced by psychedelic drugs in the human brain when users experience their mind-altering effects.The “neural fingerprint” of the psychedelic trip was spotted among hundreds of brain scans of people on LSD, psilocybin, DMT, mescaline and ayahuasca, pointing to a shared impact on the brain’s behaviour. Continue reading...